Snapshot from Aug 25, 2026 at 07:00 UTC. For live data and tracking: View Live

India & Eli Lilly and Company

14 shared events · Importance 4 · Last updated Aug 04, 2026

Importance
4
Shared Events
14
Actions
1
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
89
Business
India: India's healthcare sector benefits from the availability of a new targeted cancer therapy, Tanstrive, which addresses a specific genetic alteration in various solid tumors. This improves treatment options for Indian patients.
Eli Lilly and Company: Eli Lilly and Company has launched its cancer drug Tanstrive in India, expanding its market presence and offering a new treatment option for patients with RET-altered cancers. This launch is expected to positively impact the company's revenue and reputation in the Indian market.
Jun 25, 2026 · 7 articles
75
Business
India: India is a key battleground for weight-loss drugs due to its large obesity population and is experiencing significant competition between Novo Nordisk and Eli Lilly and Company.
Eli Lilly and Company: Eli Lilly and Company's drug Tirzepatide has been a strong competitor to Semaglutide in India, prompting Novo Nordisk to cut prices. Eli Lilly and Company has gained significant market share.
Nov 11, 2025 · 6 articles
58
International
India: As an oil-importing country, India>>> benefited from stable crude oil prices, which supported the India — Indian rupee>>>.
Eli Lilly and Company: Eli Lilly and Company>>> advanced after CVS Health>>> announced it would restore coverage for its weight-loss injection, Zepbound, and add its new obesity pill Foundayo.
May 27, 2026 · 101 articles
53
Regulatory
India: India is the country where the approval was granted; the decision addresses a significant public health burden of fatty liver disease.
Eli Lilly and Company: Eli Lilly competes with Novo Nordisk in India's obesity-drug market with Mounjaro; the approval may intensify competition.
Jul 17, 2026 · 13 articles
42
Business
India: India gains access to its first disease-modifying Alzheimer's therapy, addressing a significant dementia burden, though adoption faces challenges.
Eli Lilly and Company: Eli Lilly faces increased competition in India's Alzheimer's market as Eisai launches Leqembi, potentially impacting its Lormalzi uptake.
Aug 03, 2026 · 6 articles
42
Business
India: India's regulatory action led Lilly to pause its campaign, highlighting cross-market regulatory risks.
Eli Lilly and Company: Lilly leads GLP-1 sales in China and runs prominent awareness campaigns, though it paused its India campaign. Its Mounjaro is gaining patient demand.
Aug 24, 2026 · 6 articles
40
Business
India: India becomes the seventh country to launch Awiqli, addressing its high diabetes burden and potentially improving public health outcomes.
Eli Lilly and Company: Eli Lilly competes with Novo Nordisk in the obesity treatment market, but this launch is focused on diabetes.
Jul 09, 2026 · 21 articles
32
Business
India: Cipla's India business posted record quarterly sales of Rs 3,452 crore, growing 12%, with strong performance in chronic therapies.
Eli Lilly and Company: Cipla markets obesity drug Yurpeak under a licensing agreement with Eli Lilly; Yurpeak became the second-largest GLP-1 brand in India.
Jul 23, 2026 · 6 articles
17
Business
India: Sensex nearly unchanged.
Eli Lilly and Company: Eli Lilly's stock jumped after a committee of the European Medicines Agency recommended one of its medicines for approval, boosting its market performance.
Apr 20, 2026 · 344 articles
14
International
India: Country affected by shipping disruptions, with a ship sunk in the Red Sea, but not directly involved in Hormuz.
Eli Lilly and Company: Eli Lilly and Company raised its forecast, boosting healthcare stocks. It is not connected to the event.
Mar 09, 2018 · 316 articles
0
Business
Eli Lilly and Company: Eli Lilly and Company is a competitor in the Indian weight-loss drug market with its product Mounjaro, which has seen greater uptake than Novo Nordisk's Wegovy.
Nov 10, 2025 · 6 articles
0
Business
Dec 19, 2025 · 6 articles
0
Regulatory
Apr 03, 2026 · 8 articles
0
Business
Mar 20, 2026 · 8 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how India and Eli Lilly and Company interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.